[18F]APN-1607
Drug timelines are a Plus or Pro feature.
4 regulatory and trial events tracked for [18F]APN-1607, covering 2023-06-15 to 2026-02-20. Get the full timeline:
Most recent: Clinical Trial Update: Evaluate the Use of [18F]-APN-1607 PET in Subjects With AD-related Cognitive Impairment and Subjects With Normal Cognitive Function [Phase 3]